Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase 1 first-in-human, randomized, double–blind, placebo-controlled dose escalation trial of a single intravenous dose of the anti-herpes simplex virus monoclonal antibody HDIT101 in healthy volunteers - HDIT101-01

Next Previous
Trial Profile

A phase 1 first-in-human, randomized, double–blind, placebo-controlled dose escalation trial of a single intravenous dose of the anti-herpes simplex virus monoclonal antibody HDIT101 in healthy volunteers - HDIT101-01

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 25 Jan 2019

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs HDIT-101 (Primary)
  • Indications Herpes simplex virus infections
  • Focus Adverse reactions; First in man
  • Acronyms HDIT101-01
  • Sponsors Heidelberg ImmunoTherapeutics

Most Recent Events

  • 14 Jan 2019 Status changed from recruiting to completed.
  • 27 Jun 2018 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top